Tin tức & Cập nhật

Women with refractory overactive bladder (OAB) may improve their symptoms by using either intradetrusor onabotulinumtoxinA or combined pharmacotherapy with solifenacin and mirabegron, suggests a study.

The 2-year outcomes from the phase II BANDIT* trial confirm the potential of the Janus kinase (JAK) inhibitor baricitinib for the treatment of new-onset type 1 diabetes (T1D).

Reducing the dose of trastuzumab deruxtecan (T-DXd) does not have any significant effect on real-world (rw) progression-free survival (PFS) or treatment-related toxicities among patients with metastatic breast cancer (MBC), as shown in a Singapore study.